Impact of shear stress on Src and focal adhesion kinase phosphorylation in fibrinogen-adherent platelets
Shear stress alone can activate platelets resulting in a subsequent platelet aggregation, so-called ‘shear-induced platelet aggregation’. In our work, we analyzed how differently elevated shear stress impacts the Src and focal adhesion kinase (FAK) activation in fibrinogen-adherent human platelets. We detected the extents of Src pY418 and FAK pY397 activations in platelets on immobilized fibrinogen and over BSA under shear conditions. Moreover, we analyzed the role of αIIbβ3 in the shear-induced platelet signaling by performing our experiments in the presence of the αIIbβ3-antagonist Abciximab. Abnormally high shea...
Source: Blood Coagulation and Fibrinolysis - May 15, 2017 Category: Hematology Tags: Original Articles Source Type: research
Systemic intravenous abciximab: a novel treatment for acute central retinal artery occlusion?
(Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - May 4, 2017 Category: Opthalmology Authors: Jos é Ferreira Mendes, José Amorim, Gil Calvão‐Santos Tags: Letter to the Editor Source Type: research
Relationship between early administration of abciximab and TIMI flow in STEMI patients undergoing primary angioplasty: findings from a large regional STEMI network
Conclusion: Our results suggest that the use of abciximab, free from pharmacokinetic limits of oral P2Y12 inhibitors, should be considered in STEMI patients with early presentation before primary PCI. (Source: Journal of Cardiovascular Medicine)
Source: Journal of Cardiovascular Medicine - April 28, 2017 Category: Cardiology Tags: Research articles: Coronary artery disease Source Type: research
Use of aspirin as sole oral antiplatelet therapy in acute flow diversion for ruptured dissecting aneurysms
We present a 48-year-old man with a World Federation of Neurological Surgeons grade 5 subarachnoid hemorrhage, secondary to a ruptured intradural left vertebral artery dissecting aneurysm, who was treated successfully with a pipeline embolization device with Shield technology using aspirin and a single intravenous loading dose of abciximab. To our knowledge, this is the first case of an acute flow diversion performed using only aspirin as the sole oral antiplatelet agent. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - April 13, 2017 Category: Neurosurgery Authors: Chiu, A. H. Y., Ramesh, R., Wenderoth, J., Davies, M., Cheung, A. Tags: New devices Source Type: research
The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)
ConclusionsDespite being contraindicated in dialysis, eptifibatide was used approximately 3.5 times more frequently than abciximab among dialysis patients undergoing PCI but was associated with similar in‐hospital outcomes. (Source: Journal of Interventional Cardiology)
Source: Journal of Interventional Cardiology - April 1, 2017 Category: Cardiology Authors: Devraj Sukul, Milan Seth, Theodore Schreiber, George Hanzel, Akshay Khandelwal, Louis A. Cannon, Thomas A. Lalonde, Hitinder S. Gurm Tags: ORIGINAL INVESTIGATION Source Type: research
Ischemic Stroke After Treatment of Intraprocedural Thrombosis During Stent-Assisted Coiling and Flow Diversion [Brief Report]
Conclusions—Current protocols for treatment of intraprocedural thrombosis associated with placement of intra-arterial devices were effective in preventing ischemic stroke in ≈80% of cases. Current smoking was the only independent predictor of ischemic stroke. (Source: Stroke)
Source: Stroke - March 27, 2017 Category: Neurology Authors: Nimer Adeeb, Christoph J. Griessenauer, Justin M. Moore, Paul M. Foreman, Hussain Shallwani, Rouzbeh Motiei-Langroudi, Raghav Gupta, Carlos E. Baccin, Abdulrahman Alturki, Mark R. Harrigan, Adnan H. Siddiqui, Elad I. Levy, Christopher S. Ogilvy, Ajith J. Tags: Cerebral Aneurysm, Ischemic Stroke Brief Reports Source Type: research
Use of Abciximab and Heparin Can Safely Facilitate LVAD Implantation in Patients with Heparin-Induced Thrombocytopenia
We describe our strategy to use abciximab, glycoprotein IIb/IIIa receptor inhibitor, and heparin in patients who underwent LVAD implantation with HIT. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - March 25, 2017 Category: Transplant Surgery Authors: C. Lee, P.C. Colombo, D. Jennings, J. Han, M.B. James, M.A. Wright, K. Takeda, P.A. Kurlansky, M. Yuzefpolskaya, A.R. Garan, C. Chan, Y. Naka, H. Takayama Source Type: research
Emergent carotid stenting and intra-arterial abciximab in acute ischemic stroke due to tandem occlusion
. (Source: British Journal of Neurosurgery)
Source: British Journal of Neurosurgery - March 16, 2017 Category: Neurosurgery Authors: Fawaz Al-Mufti Krishna Amuluru Nathan W. Manning Imad Khan Lissa Peeling Chirag D. Gandhi Charles J. Prestigiacomo Galyna Pushchinska David Fiorella Henry H. Woo Source Type: research
Plasma Kallikrein enhances platelet aggregation response by subthreshold doses of ADP.
Abstract
Human plasma kallikrein (huPK) potentiates platelet responses to subthreshold doses of ADP, although huPK itself, does not induce platelet aggregation. In the present investigation, we observe that huPK pretreatment of platelets potentiates ADP-induced platelet activation by prior proteolysis of the G-protein-coupled receptor PAR-1. The potentiation of ADP-induced platelet activation by huPK is mediated by the integrin αIIbβ3 through interactions with the KGD/KGE sequence motif in huPK. Integrin αIIbβ3 is a cofactor for huPK binding to platelets to support PAR-1 hydrolysis that contributes to ...
Source: Biochimie - January 19, 2017 Category: Biochemistry Authors: Ottaiano TF, Andrade SS, de Oliveira C, Silva MC, Buri MV, Juliano MA, Girão MJ, Sampaio MU, Schmaier AH, Wlodawer A, Maffei FH, Oliva ML Tags: Biochimie Source Type: research
Intra-arterial Use of Abciximab in thromboembolic complications associated with cerebral aneurysm coiling: The London Ontario experience
and Purpose: Experience with intra-arterial infusion of abciximab for the treatment of endovascular thrombotic complications is limited to short case series. Our objective is to evaluate the safety and effectiveness of this drug for the treatment of thromboembolic complications during aneurysm coiling and determine the risk factors. (Source: World Neurosurgery)
Source: World Neurosurgery - January 15, 2017 Category: Neurosurgery Authors: R. Mart ínez-Pérez, S.P. Lownie, D.M. Pelz Tags: Original article Source Type: research
Intra-arterial versus intravenous abciximab therapy for thromboembolic complications of neuroendovascular procedures: case review and meta-analysis
Conclusions
Abciximab produces a high rate of angiographic improvement and a low incidence of postprocedural infarct in neuroendovascular procedures complicated by thromboemboli. IA abciximab produces greater angiographic improvement than IV treatment. Postprocedural infarction is less common in patients with complete angiographic response than in those with partial or no response. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - January 12, 2017 Category: Neurosurgery Authors: Kansagra, A. P., McEachern, J. D., Madaelil, T. P., Wallace, A. N., Cross, D. T., Moran, C. J., Derdeyn, C. P. Tags: Ischemic stroke Source Type: research
Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
ConclusionsThis unbiased synthesis of the literature exposed significant differences in the extent of published evidence between molecules at preclinical, clinical, and post-marketing stages of development, providing clinicians and payers with a consolidated view of the available data and remaining gaps. (Source: BioDrugs)
Source: BioDrugs - November 1, 2016 Category: Drugs & Pharmacology Source Type: research
Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia.
Abstract
HIT is an acquired antibody-mediated disorder strongly associated with thrombosis, including microthrombosis secondary to disseminated intravascular dissemination (DIC). The clinical features of HIT are reviewed from the perspective of the 4Ts scoring system for HIT, which emphasises its characteristic timing of onset of thrombocytopenia. HIT antibodies recognize multimolecular complexes of platelet factor 4 (PF4)/heparin. However, a subset of HIT sera recognise PF4 bound to platelet chondroitin sulfate; these antibodies activate platelets in vitro and in vivo even in the absence of heparin, thus ...
Source: Thrombosis and Haemostasis - September 21, 2016 Category: Hematology Authors: Warkentin TE Tags: Thromb Haemost Source Type: research
Delayed severe abciximab-induced thrombocytopenia: A case report
Conclusion Although specific mechanisms of abciximab-related thrombocytopenia are still unclear and the management is not well established, the patient responded well to the therapy and his recovery was uneventful. (Source: Heart and Lung: The Journal of Acute and Critical Care)
Source: Heart and Lung: The Journal of Acute and Critical Care - September 21, 2016 Category: Respiratory Medicine Source Type: research
